Oct 7, 2020 6:30 am EDT Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Sep 30, 2020 8:00 am EDT Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President
Sep 18, 2020 9:30 am EDT Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study
Sep 18, 2020 7:00 am EDT Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study
Sep 10, 2020 5:30 am EDT Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) Virtual Conference
Aug 6, 2020 4:05 pm EDT Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
Jul 31, 2020 8:30 am EDT Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications